Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. - Wikidata - awgldk - TriplyDB

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

http://www.wikidata.org/entity/Q36747784

about

The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Peste des petits ruminants virus infection of small ruminants: a comprehensive review.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Capturing the natural diversity of the human antibody response against vaccinia virus Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.The strategic use of novel smallpox vaccines in the post-eradication world.Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

P2860

Q26996686-A4F11AB2-369B-45BE-BE72-55BE87D6BBF1 Q27684713-1253E2D5-9AD7-4B5F-9747-24C972B9B4DF Q33508318-8557BE19-4931-4648-9737-D395C6E2B0C6 Q33725635-9EAC3615-EA08-4FBE-9AA5-8F8701A2FC64 Q33820705-0095F14E-F156-4F19-8231-A52AD250DB05 Q34126697-3947C387-6BD4-47EB-9265-04B822B41D70 Q34470311-CF90D558-E019-4540-B1D5-77907E3EBAB9 Q34502997-B4932E37-912F-40E7-AA03-E15A18A463EA Q34529713-A51C0F7E-501C-4555-A1BB-EE6E1AB65C66 Q35192889-00F616DC-3B58-464D-80CA-FA1DA111FE29 Q35226200-974D2224-5FDF-4C7B-923D-2A2E14240775 Q35339702-755D6D19-CB1C-42DA-8519-403CD95B5F0E Q35667240-C6DAB042-98FE-443D-B4AB-8A6902FE9198 Q35826728-75050248-46FE-44D1-AAE9-343A7C68822E Q35830974-59F0B53C-3AAE-4DA2-A661-0D599BA07D61 Q36559636-73FC1886-01A3-4EE3-8272-885E2A0DEBEE Q37107609-EE34CB8E-D564-495D-97CC-D44ED841ECA1 Q37174356-8CA79205-F2ED-43F2-8D4B-C959819491DA Q37301894-1620E9A5-A553-4EC5-87BC-2C8B78F59F49 Q37461110-EEA5241F-DA93-4280-8AA3-7422BA6CF120 Q37791160-B2777E13-BE03-4FD1-9F83-C2C33D67DA03 Q37909421-B6128E0D-5AF0-4E56-B570-792BB387542B Q40675201-397A7461-5EA3-46CB-BA4E-50FD1A53CDF7 Q40757700-D9B0084C-F552-443F-A377-82CCB44F4843

P2860

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

http://www.wikidata.org/entity/Q36747784

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Differential antigen requireme ...... inia virus challenges in mice.

@en

type

label

Differential antigen requireme ...... inia virus challenges in mice.

@en

prefLabel

Differential antigen requireme ...... inia virus challenges in mice.

@en

P1433

Q36747784-0B89FF6D-8180-4256-AB9B-3DE9401393C0

P1476

Q36747784-324B831D-6E66-45BD-89E9-25BC282065A3

P2093

Q36747784-1CABDB49-3A21-4DB2-A27D-DA6EAA23F519

Q36747784-1FEF3C2A-F220-4BA3-9B36-DD5842FE44E0

Q36747784-24F2DDE8-1C84-43F7-A36B-C20BF9BE72CE

Q36747784-8C3FF346-8078-4A46-A0B7-6E66A303C12C

Q36747784-8F12A4BB-A911-4531-9089-4AF59A55E83D

Q36747784-9A653D6A-09AD-48D2-A5E6-44A2BF420016

Q36747784-A964E96D-0EAC-4828-B2FF-C50EAE8B5560

Q36747784-C918341F-1AC0-4C8A-8E54-F4D101C71D70

Q36747784-DDC9F334-718A-47B1-A4D4-D58D74075B6D

Q36747784-E62AF22C-4545-4F9C-993A-FC2DA51E3934

P2860

Q36747784-0F51EBD3-851C-41E0-809D-D285D4859F48

Q36747784-1152C20B-CA72-4344-A11F-5382B4F7C725

Q36747784-129EC872-6BA3-40A2-80B1-DB93A114DB0F

Q36747784-1CF248B4-4A65-4169-87BD-67AEA06A231E

Q36747784-26497FD6-3676-49C9-9843-55996F21EDDD

Q36747784-2A95416A-B184-448F-81A0-40D10025DB28

Q36747784-314348DA-EA49-4B10-97C4-8945E1F3FC31

Q36747784-45EA5268-036E-4644-9300-1EC192C9C5E4

Q36747784-53A4388D-9F69-4274-950D-C37B5FD12247

Q36747784-66653000-0CD2-4D80-B2A4-26D012FCD1FF

P304

Q36747784-DEF4616C-756C-4B9A-935E-F00675D1923E

P31

Q36747784-979D54CF-54FD-41DF-9694-C3A4F93F1191

P356

Q36747784-887CED74-395F-49F2-8B13-09816E4F5EE4

P407

Q36747784-6688E9D7-6218-40D9-A9A0-DB2D020C11C0

P433

Q36747784-774B5754-8505-4342-BB42-06CF64E144EB

P478

Q36747784-02D1D712-46DF-484D-892C-E1CBD10029F7

P50

Q36747784-11925BE7-0F46-4127-9906-738D47E3720D

Q36747784-47906C15-45C1-408B-84CF-A479B0F96344

Q36747784-483DBBB1-1EF6-4721-A18F-1463D2D3B502

P577

Q36747784-188DFCCA-BF12-4FED-B332-B0A569F653FA

P698

Q36747784-80F6A37B-E02C-4989-A058-2399D4A4402D

P932

Q36747784-C7A2A0DC-A150-48E4-99FF-9344184112E3

P356

P1433

Journal of Virology

P1476

Differential antigen requireme ...... inia virus challenges in mice.

@en

P2093

Ayush Giri

http://www.w3.org/2001/XMLSchema#string

Bonnie A Ewald

http://www.w3.org/2001/XMLSchema#string

Colleen Devoy

http://www.w3.org/2001/XMLSchema#string

David R Kaufman

http://www.w3.org/2001/XMLSchema#string

Genoveffa Franchini

http://www.w3.org/2001/XMLSchema#string

Lauren E Grandpre

http://www.w3.org/2001/XMLSchema#string

Lennart Holterman

http://www.w3.org/2001/XMLSchema#string

Matthew Denholtz

http://www.w3.org/2001/XMLSchema#string

Menzo J E Havenga

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Adverse events associated with smallpox vaccination in the United States, January-October 2003.

Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004.

Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge

The formation and function of extracellular enveloped vaccinia virus.

Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

P304

6829-6837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00353-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Heraud

P577

2008-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18448519

http://www.w3.org/2001/XMLSchema#string

P932

2446990

http://www.w3.org/2001/XMLSchema#string